title: Relapsed Acute Myeloid Leukemia: Need for Innovative Treatment Strategies to Improve Outcome.
abstract: Relapse continues to be a major hurdle in achieving cure in patients with acute myeloid leukemia (AML). The outcome after relapse is not uniform in all patients with AML and is dependent on several prognostic variables, including age, cytogenetics at initial diagnosis, duration of first complete remission, whether an allogeneic stem cell transplant was performed during first complete remission, and the presence of a number of molecular aberrations. Despite extensive research over the past several decades, there is no standard of care for treating patients with relapsed AML. This is possibly due to the accrual of patients with widely different disease profiles in most trials for relapsed AML. With increasing insights into the disease biology based on identification of pathogenic and aberrant molecular and cellular pathways, novel therapeutic strategies are emerging. Hopefully in the near future, we can improve the outcome of patients with relapsed AML with treatment strategies based on identification of specific targets and methods to overcome these aberrant processes.
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
authors: Talha
authors: T
authors: Badar
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: fravandi@mdanderson.org.
authors: Farhad
authors: F
authors: Ravandi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D011379:Prognosis; D012008:Recurrence; D016896:Treatment Outcome
keywords: AML; Molecular targets; Novel agents; Outcome; Relapse